Nicolas P Andrews, Justin X Boeckman ... James S Trimmer
This paper describes an effective pipeline for conversion of conventional monoclonal antibodies into recombinant form that results in an IgG subclass switch that greatly expands their utility for multiplex labeling.
Keith F DeLuca, Jeanne E Mick ... Jennifer G DeLuca
Tools and methodologies to create and diversify recombinant antibodies and antibody fragments provide researchers with the ability to generate low-cost, high-yield immunological reagents.
Open science and consensus antibody validation protocols can identify high-quality, renewable antibodies for the ~50% of the human proteome currently covered, enabling robust and reproducible biomedical research.
A fully synthetic library of humanized single domain antibodies yields in vitro high affinity antibodies usable in cell biology and translational projects.
Yiska Weisblum, Fabian Schmidt ... Paul D Bieniasz
SARS-CoV-2 spike variants that resist neutralization by therapeutic antibodies or convalescent plasma can be generated in the laboratory and exist at low frequency in natural populations.
Takashi Watanabe, Hikaru Hata ... Hidehiro Fukuyama
A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a crucial advance for pandemic preparedness.
By fusing influenza viral conserved epitopes and a superantigen fragment, we constructed a recombinant protein that might be a candidate universal broad-spectrum vaccine for the prevention and treatment of multiple influenza viruses.
Alexander J Martinko, Charles Truillet ... James A Wells
Proteomics and functional genomics coupled to an antibody discovery pipeline revealed the influence of oncogenic RAS signaling on the cell-surface proteome and resulted in the discovery of potential therapeutic targets for RAS-driven cancers.
Justin YA Doritchamou, Jonathan P Renn ... Patrick E Duffy
VAR2CSA, the leading candidate antigen for a placental malaria vaccine, displays epitopes targeted by naturally acquired broadly neutralizing antibodies of African multigravidae.
There is an ongoing need for researchers and all stakeholders to better understand issues surrounding antibody characterization to improve the quality and reproducibility of research that employs these reagents.
